LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, will be presenting at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time.
There will be simultaneous and archived webcasts available at https://wsw.com/webcast/jeff302/rdnt/1856896 and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.
Details for RadNet's Presentation:
| Date: | Wednesday, June 5, 2024 | |
| Time: | 11:30 a.m. Eastern Time | |
| Location: | New York, NY |
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 375 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, Texas and Arizona. In addition, RadNet provides radiology information technology and artificial intelligence solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,700 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928

| Last Trade: | US$73.15 |
| Daily Change: | 0.21 0.29 |
| Daily Volume: | 282,652 |
| Market Cap: | US$5.650B |
December 01, 2025 November 30, 2025 November 20, 2025 November 17, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load